Table 2.
Association between the levels at baseline serum of sNKG2DLs and the disease control of melanoma patients.
| sNKG2DLs a | Immune checkpoint treatment b | DCR c | pd | Control e | DCR | p | |
|---|---|---|---|---|---|---|---|
| MICA | + | 22 | 45.7 | 0.99 | 16 | 32.5 | 0.24 |
| − | 171 | 45.6 | 42 | 45.2 | |||
| MICB | + | 42 | 42.9 | 0.72 | 19 | 36.8 | 0.16 |
| − | 151 | 46 | 39 | 56.4 | |||
| ULBP-1 | + | 85 | 32.9 | 0.002 | 35 | 54.3 | 0.42 |
| − | 77 | 57.1 | 23 | 43.5 | |||
| ULBP-2 | + | 45 | 44.4 | 0.86 | 9 | 44.4 | 0.72 |
| − | 148 | 45.9 | 49 | 51 | |||
| ULBP-3 | + | 77 | 49.4 | 0.39 | 23 | 43.5 | 0.42 |
| − | 116 | 43.1 | 35 | 54.3 | |||
a
: detection of sNKG2DLs (MICA, MICB, ULBP-1,2,3) in the pre-treatment serum of melanoma patients; positive (+) or negative (−) measurement (ng/mL) of sNKG2DLs in the patients' serum;
b
: Number of subjects from the cohort of patients treated with immune checkpoint blockade agents;
c
: disease control rate (DCR) expressed as the percentage of patients with complete responses (CR), partial responses (PR), and stable disease (SD) according the immune-related response criteria assessment; see Refs. [45],[46];
d
: p value obtained from chi-squared test analysis;
e
: number of patients from the control cohort.